Editors’ Picks, April 2024: Targeting Metabolism, KRAS, and More
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
SAN DIEGO – A video designed to educate Black men about prostate cancer resulted in 97% of surveyed participants...
SAN DIEGO – Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated...
SAN DIEGO – AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent...
SAN DIEGO – A blood-based machine learning assay that combines cell-free DNA (cfDNA) fragment patterns and levels of the...
SAN DIEGO – TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease...
Patricia M. LoRusso, DO, PhD (hc), FAACR, begins term as AACR President SAN DIEGO – The members of the...
SAN DIEGO – An investigational exosome-based liquid biopsy accurately detected 97% of stage 1-2 pancreatic cancers when combined with...
Drug has higher selectivity for PARP1, improving safety and tolerability SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP...
SAN DIEGO – A combination of the KRASG12C inhibitor adagrasib (Krazati) and the anti-epidermal growth factor receptor (EGFR) antibody...
The investigational therapy uses a cold-temperature probe to kill a portion of prostate cancer cells and release tumor-specific neoantigens...